« Back
Home /
MMAE-d8

MMAE-d8

Item no.	HY-15162A-1mg*5
Manufacturer	MedChem Express
CASRN	2070009-72-0
Amount	1 mg x 5
Quantity options	10 mMx1 mL 10 mg 1 mg 1 mg x 10 1 mg x 5 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.29
Citations	[1]Li F, et al. Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models. Cancer Res. 2016 May 1;76(9):2710-9.
Smiles	O=C(N([C@@H]([C@@H](C)CC)[C@H](OC)CC(N1[C@H]([C@H](OC)[C@@H](C)C(N[C@H](C)[C@@H](O)C2=CC=CC=C2)=O)CCC1)=O)C)[C@@]([2H])(NC([C@@H](NC)C(C)C)=O)C([2H])(C([2H])([2H])[2H])C([2H])([2H])[2H]
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	Monomethyl auristatin E-d8,Deuterated labeled MMAE
Shipping Condition	Room temperature
Available
Manufacturer - Type	Isotope-Labeled Compounds
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	ADC Cytotoxin; Microtubule/Tubulin
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	726.03
Product Description	MMAE-d8 is a deuterated labeled MMAE, a potent mitotic inhibitor and a tubulin inhibitor.
Manufacturer - Research Area	Cancer
Solubility	DMSO: 100 mg/mL (ultrasonic)
Manufacturer - Pathway	Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; Cytoskeleton
Isoform	Auristatin
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-15162A-1mg*5-safety-datasheet.pdf